NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced new Deputy NRG National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Chair and Vice Chair of the NRG Veteran Affairs & Military Treatment Facility (VA-MTF) Subcommittee.
Julie Bauman, MD, MPH, was appointed Deputy Chair of NRG’s NCORP Research Base replacing Dr. Lisa Kachnic who was recently named an NRG NCORP Multi-Principal Investigator (MPI). Dr. Bauman will continue to serve as Chair of the NRG Cancer Prevention Committee. She also is a core member of the NRG Head and Neck Cancer Committee. She has led several major trials within the organization including NRG-HN003 and NRG-RTOG 1216. Outside of NRG, Dr. Bauman is the Dr. Cyrus Katzen Family Director of the George Washington (GW) University Cancer Center, and the Associate Dean of Cancer and Professor of Medicine at the GW School of Medicine and Health Sciences. She is the MPI and Medical Director of the University of Arizona Cancer Prevention Clinical Trials Network which performs early phase cancer prevention trials evaluating surrogate biomarker modulation by candidate chemoprevention agents across multiple organ sites. She also currently serves as the Co-Chair of the NCI Cancer Prevention Steering Committee and the Co-Chair of the Previously Untreated Locally Advanced Task Force of the NCI Head and Neck Cancer Steering Committee.
Ryan Burri, MD, was selected as the VA-MTF Subcommittee Vice Chair replacing Maria Kelly who recently stepped down from the role. Dr. Burri is a radiation oncologist at the Bay Pines Veterans Affairs Healthcare System. Dr. Burri led the effort at his site to become the first VA NRG primary member in the nation and has since opened and enrolled patients on several NRG trials. He currently is the site Principal Investigator at Bay Pines for NRG, leading multiple studies including NRG-CC005 “FORTE”, NRG-GU009 “PREDICT-RT”, NRG-GU010 “GUIDANCE”, and NRG-HN009. Outside of his involvement in NRG, Dr. Burri is also the Assistant Chief of Radiation Oncology Services and a staff physician at the CW Young VA Medical Center as well as a member of the American Society for Radiation Oncology (ASTRO). Dr. Burri serves as the local Principal Investigator at his site for several other studies outside of the NRG portfolio including the KRYSTAL-7 lung cancer study as well as the VA STARPORT, the ONCOMINE, and the CHOMP prostate cancer studies.
NRG looks forward to the continued advances of the group’s research through the leadership and guidance of these individuals in their new roles.
Current NRG Oncology openings for leadership and committee applications can be found on the website at www.NRGOncology.org/Current-Openings
About NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.